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Abstract
Considering the recommended indications for Helico-
bacter pylori  (H. pylori ) eradication therapy and the 
broad spectrum of available diagnostic methods, a 
reliable diagnosis is mandatory both before and after 
eradication therapy. Only highly accurate tests should 
be used in clinical practice, and the sensitivity and 
specificity of an adequate test should exceed 90%. The 
choice of tests should take into account clinical circum-
stances, the likelihood ratio of positive and negative 
tests, the cost-effectiveness of the testing strategy and 
the availability of the tests. This review concerns some 
of the most recent developments in diagnostic methods 
of H. pylori  infection, namely the contribution of novel 
endoscopic evaluation methodologies for the diagnosis 
of H. pylori  infection, such as magnifying endoscopy 
techniques and chromoendoscopy. In addition, the di-
agnostic contribution of histology and the urea breath 
test was explored recently in specific clinical settings 
and patient groups. Recent studies recommend en-
hancing the number of biopsy fragments for the rapid 
urease test. Bacterial culture from the gastric biopsy is 
the gold standard technique, and is recommended for 
antibiotic susceptibility test. Serology is used for initial 
screening and the stool antigen test is particularly used 
when the urea breath test is not available, while molec-
ular methods have gained attention mostly for detect-
ing antibiotic resistance.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Key words: Helicobacter pylori ; Diagnosis; Endoscopy; 
Histology; Culture; Urea breath test; Stool antigen test; 
Serology; Molecular methods
Core tip: Considering the importance of a reliable di-
agnosis in the setting of current recommendations for 
Helicobacter pylori  (H. pylori ) eradication therapy, re-
cent developments in both invasive and non-invasive 
methods may further contribute to improving H. pylori  
detection. The manuscript presents an extensive over-
view of the major advances in endoscopy, histology, 
culture, urea breath test, serology, stool tests and mo-
lecular methods, emphasizing their major contributions 
and potential shortcomings.
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TOPIC HIGHLIGHT
INTRODUCTION
A reliable primary diagnosis and control of  treatment 
success of  Helicobacter pylori (H. pylori) infection is crucial 
for patients with a wide spectrum of  H. pylori-related 
conditions, including uncomplicated or complicated ulcer 
disease, mucosa associated lymphoid tissue (MALT) lym-
phoma, atrophic gastritis and previous partial gastric re-
section for gastric cancer. Accurate diagnosis of  H. pylori 
infection involves the combined knowledge, effort and 
research of  laboratories, gastroenterologists and patholo-
gists. Traditional diagnosis is made using a combination 
of  tests, both invasive and noninvasive. Considering the 
broad spectrum of  diagnostic methods, only highly accu-
rate tests should be used in clinical practice under specific 
circumstances and currently, the sensitivity and specific-
ity of  such tests should exceed 90%. The choice of  tests 
usually depends on clinical circumstances, the likelihood 
ratio of  positive and negative tests, the cost-effectiveness 
of  the testing strategy and of  the availability of  the tests. 
The present paper aimed to present an overview of  the 
most recent advances in both biopsy- and non-biopsy-
based diagnostic methods for H. pylori infection (Table 1).
ENDOSCOPY 
Considering that accurate prediction of  H. pylori infection 
status on endoscopic images can improve early detection 
of  gastric cancer, especially in some geographic areas, the 
contribution of  both conventional and novel endoscopic 
evaluation methodologies has received increased atten-
tion, particularly in specific clinical settings. A summary 
of  the latest endoscopic studies is presented below. Wata-
nabe et al[1] studied the diagnostic yield of  endoscopy 
for H. pylori infection at three endoscopist career levels 
- beginner, intermediate and advanced. For this study, 
77 consecutive patients who underwent endoscopy were 
analyzed for H. pylori infection status by histology, serol-
ogy and urea breath test (UBT). The diagnostic yield was 
88.9% for H. pylori-uninfected, 62.1% for H. pylori-in-
fected, and 55.8% for H. pylori-eradicated. Intra-observer 
agreement for H. pylori infection status was good (k > 
0.6) for all physicians, while inter-observer agreement 
was lower (k = 0.46) for beginners than for intermediate 
and advanced (k > 0.6). For all physicians, good inter-
observer agreement in endoscopic findings was seen for 
atrophic change (k = 0.69), but the accuracy was lower 
for beginners.
In 496 asymptomatic Japanese middle-aged men, a 
prospective evaluation (mean follow-up period of  54 
years), of  gastric cancer development was performed in 
non-atrophic stomachs with highly active inflammation 
identified by serum levels of  pepsinogen and H. pylori 
antibody, together with a specific endoscopic feature: 
endoscopic rugal hyperplastic gastritis (RHG) (reflecting 
localized highly active inflammation)[2]. Cancer incidence 
was significantly higher in patients with RHG, high H. 
pylori antibody titers and low PG Ⅰ/Ⅱ ratio than in pa-
tients without. Significantly, no cancer development was 
observed in these high-risk subjects after H. pylori eradi-
cation. This study emphasizes the high risk of  cancer 
development in subjects with H. pylori-associated highly 
active non-atrophic gastritis and the utility of  the two 
serological tests and endoscopic RHG for their identifica-
tion.
Considering that H. pylori eradication is essential for 
metachronous gastric cancer prevention in patients un-
dergoing endoscopic mucosectomy (EMR) for early gas-
tric cancer, as reported by Fukase et al[3], Lee et al[4] aimed 
to determine the optimal biopsy site for H. pylori detec-
tion in the atrophic remnant mucosa of  91 EMR patients. 
Three paired biopsies for histology were taken at the 
antrum, corpus lesser (CLC), and greater curve (CGC). 
Additional specimens were obtained at the antrum and 
CGC for a rapid urease test (RUT). H. pylori infection was 
defined as at least two positive specimens on histology 
and/or RUT. Pepsinogen levels were used to determine 
serological atrophy. The authors concluded that CGC 
is the optimal biopsy site for H. pylori diagnosis in EMR 
patients with extensive atrophy and that an antral biopsy 
should be avoided, especially in serologically atrophic pa-
tients.
Although gastroscopic biopsy-based tests such as the 
RUT, histological examination, and culture have been 
widely used to diagnose H. pylori infection, many investi-
gators have attempted to categorize the endoscopic find-
ings characteristic of  an H. pylori-infected stomach.
In 2002, Japanese endoscopists[5] found that collecting 
venules, seen as numerous minute red dots in the gastric 
corpus, were a characteristic finding in the normal stom-
ach without H. pylori infection, using both standard and 
magnifying endoscopy (identification of  micromucosal 
patterns). This finding was termed “regular arrangement 
of  collecting venules” (RAC). However, these findings 
are not a reliable method of  diagnosis because of  their 
low sensitivity and specificity. 
Although magnifying endoscopy provides more 
precise information concerning abnormal mucosal pat-
terns[6,7], it is not available in all endoscopy units. More-
over, its use requires training under an experienced super-
visor and expertise. In addition, magnifying endoscopy 
is not necessarily appropriate for routine clinical practice 
because it is time-consuming and only a few facilities 
carry out this technique on a routine basis. On the other 
hand, endoscopic features corresponding to Sydney Sys-
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Endoscopy Invasive Yes No
Histology Invasive Yes No
Rapid urease test Invasive No No
Culture Invasive Yes Yes
Molecular methods Both No Yes
Serology Noninvasive No No
Urea breath test Noninvasive No No
Stool antigen test Noninvasive No No
tem pathological findings have not yet been identified, 
and the diagnosis of  H. pylori infection in the gastric mu-
cosa by endoscopic features has not yet been established 
(Figure 1). In this setting, the Study Group of  Japan 
Gastroenterological Endoscopy Society for Establishing 
Endoscopic Diagnosis of  Chronic Gastritis performed 
a prospective multicenter study enrolling 275 patients[8], 
investigating the association between endoscopic findings 
(conventional findings and indigo carmine contrast) and 
histological diagnosis of  H. pylori (antrum and corpus). 
It was shown that specific endoscopic findings, such as 
diffuse redness, spotty redness and mucosal swelling as-
sessed by conventional endoscopy and swelling of  areae 
gastricae by the indigo carmine contrast method, were use-
ful for diagnosing H. pylori infection. 
Cho et al[9] aimed to establish a new classification for 
predicting H. pylori-infected stomachs by non-magnifying 
standard endoscopy alone. A total of  617 participants 
who underwent gastroscopy were enrolled prospectively 
and a careful close-up examination of  the corpus at the 
greater curvature was performed, maintaining a distance 
of  10 mm between the endoscope tip and the mucosal 
surface. Despite being a monocenter study in which 
standard endoscopy was not directly compared with mag-
nifying endoscopy, these results suggest two important 
contributions for prediction of  H. pylori infection status: 
(1) the observation of  gastric mucosal patterns using 
standard endoscopy and proposal of  a new endoscopic 
classification including a normal RAC and three abnor-
mal mucosal patterns; and (2) an accuracy of  prediction 
of  H. pylori positivity at least similar to that reported in 
magnifying endoscopy studies (sensitivity of  95.2% and 
specificity of  82.2%)[10]. In the future, multicenter trials 
comparing standard endoscopy against magnifying en-
doscopy, including changes in mucosal patterns after H. 
pylori eradication, and including endoscopists with differ-
ent levels of  expertise, are needed to confirm the reliabil-
ity of  these data.
Chromoendoscopy has also regained attention re-
cently as an additional methodology to detect H. pylori in 
the gastric mucosa. A multicenter Japanese study involv-
ing 275 patients evaluated the possibility of  diagnosing 
H. pylori by conventional endoscopy and chromoendos-
copy using indigo carmine compared with histology 
performed according to the Sydney System[7]. Based on 
several indices, the authors obtained a sensitivity of  94% 
in the corpus and 88% in the antrum. However, the spec-
ificities in the corpus and in the antrum were low (62% 
and 52%, respectively). Another study using a Cuban 
adult population[11] also aimed to evaluate the diagnostic 
yield of  chromoendoscopy with red phenol at 0.1% for 
the detection of  H. pylori infection against histology. This 
study reported a sensitivity of  72.6% (95%CI: 64.9-79.2) 
and a specificity of  75.5% (95%CI: 61.9-85.4). The au-
thors concluded that it might be a useful method to diag-
nose H. pylori infection in the gastric mucosa, potentially 
with some specific advantages (topographic localization, 
avoidance of  contamination and fast and immediate read-
ing).
HISTOLOGY 
Although histology has been considered to be the gold 
standard for H. pylori detection, the influence of  clinical 
practice on the histopathological detection of  H. pylori in-
fection has been insufficiently explored. Recognizing that 
the number and distribution of  H. pylori organisms vary 
in patients taking proton pump inhibitors (PPIs), it has 
been recommended to discontinue PPIs two weeks be-
fore endoscopy and to take biopsies from both the body 
and the antrum. 
In a representative study, Lash et al[12] aimed to evalu-
ate the yield of  different gastric sampling strategies and 
to determine the adherence to the Sydney System guide-
lines in a nationwide sample of  endoscopists in United 
States. Using a database of  biopsy records diagnosed at a 
single pathology laboratory, the results of  gastric biopsies 
taken to evaluate gastric inflammatory conditions in pa-
tients with no endoscopic lesions were reviewed. The in-
cisura angularis, rarely sampled, yielded minimal additional 
diagnostic information and the acquisition of  at least 
two biopsy specimens from the antrum and corpus, es-
sentially following the Sydney System recommendations, 
was confirmed as a sensible strategy that guarantees the 
maximum diagnostic yield for the most common gastric 
inflammatory conditions.
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Figure 1  Endoscopic features of Helicobacter pylori infection (antral nodularity). 
BA
Lopes AI et al . H. pylori  diagnosis advances
for H. pylori, with the lowest rate of  inter observer varia-
tion and is much faster than conventional histology[19]. 
However, the necessity for routine special stains and/or 
IHC stains has been debated in recent years. A recent 
study by Wang et al[20] confirmed what many pathologists 
assume: routine special stains, specifically IHC stains, are 
not cost-effective or necessary. Recently, Smith et al[21], in 
a retrospective study involving 200 consecutive gastric 
biopsy specimens, further confirmed that H. pylori is eas-
ily observed in the majority of  cases with HE (sensitivity 
91% and specificity 100%), remaining the most expedient 
and least expensive test for identifying H. pylori in gastric 
biopsies. 
An institutional quality assurance study of  a conven-
tional method for the diagnosis of  H. pylori - associated 
gastritis was performed by Hartman et al[22] in the United 
States, based on head-to-head evaluation by four meth-
ods, HE stain, Giemsa stain, Warthin-Starry stain, and H. 
pylori immunostaining of  356 gastric biopsy specimens. 
About 83% of  H. pylori gastritis identified were diag-
nosed on the initial HE-stained slides, further supporting 
the use of  routine ancillary stains to diagnose H. pylori 
infection in gastric biopsy specimens. Usually, the use of  
special stains is only recommended for biopsy specimens 
with moderate to severe chronic active or inactive gastri-
tis in which H. pylori is not identified by HE staining, for 
post-treatment biopsy specimens and in cases in which 
structures “suspicious”, but not definitive, for H. pylori 
are observed by HE staining[23]. 
Both routine conventional histology-based methods 
and novel methods for H. pylori detection have increas-
ingly focused on specific clinical settings and patient 
groups (bleeding peptic ulcer, gastric cancer). False-
negative results may occur when using histological and 
RUT to detect H. pylori in biopsy specimens obtained 
during peptic ulcer bleeding episodes (PUB). Choi et al[24] 
evaluated different diagnostic methods in the specific 
setting of  peptic ulcer, concluding that histology was the 
most accurate test, regardless of  bleeding, compared with 
culture, serology and RUT. Ramirez-Lazaro et al[25] found 
that IHC and real-time PCR methods might improve the 
sensitivity of  biopsy-based diagnosis in this specific set-
ting (PUB).
In patients submitted to a subtotal gastrectomy due 
to gastric cancer, the identification and treatment of  
H. pylori are the key points in the prevention of  cancer 
recurrence. Xu et al[26] evaluated the predictive value of  
neutrophil infiltration, a hallmark of  active inflammation 
(updated Sydney system), as a histological marker of  H. 
pylori infection, in 315 dyspeptic patients undergoing up-
per gastrointestinal endoscopy, including patients with a 
subtotal gastrectomy. The diagnosis of  H. pylori infection 
was based on UBT and on anti-H. pylori immunoglobulin 
G (IgG) antibody in patient with a subtotal gastrectomy. 
Although neutrophil infiltration of  gastric mucosa was 
strongly associated with overall H. pylori infection, in pa-
tients with a subtotal gastrectomy, the diagnostic accuracy 
of  neutrophil infiltration in H. pylori infection was low.
In a Canadian study[13], electronic patient records were 
evaluated for the sites of  gastric sampling and PPI use at 
endoscopy, collecting 150 cases with biopsies taken from 
both the antrum and body, which were randomly selected 
for pathological re-review with special stains. The gastric 
regions sampled, H. pylori distribution and influence of  
clinical factors on pathological interpretation were as-
sessed. This study confirmed that, despite national and 
international guidelines for managing H. pylori infection, 
these guidelines are infrequently adhered to, with PPIs 
frequently contributing to false diagnosis, and sampling 
only one region increases the likelihood of  missing active 
infection by at least 15%.
Considering that atrophy of  the stomach mucosa 
develops in about 50% of  H. pylori infected individuals 
by the age of  65, and is considered a pre-malignant le-
sion for gastric cancer[14-16], H. pylori eradication is recom-
mended in the presence of  atrophy[17], because atrophy 
may reverse after successful eradication therapy. It is 
critically important and challenging, therefore, to deter-
mine the presence or absence of  H. pylori in patients with 
atrophic gastritis. During atrophy progression, however, 
the density of  H. pylori in the stomach mucosa decreases, 
and may disappear completely during the late stages of  
atrophy[14,16]. This may explain the markedly lower sen-
sitivity of  biopsy-based tests (RUT, histology, culture) 
in the presence of  atrophy. Similarly, UBT and antigen 
stool detection can also give false-negative results in these 
circumstances. In contrast, serology is not influenced to 
such an extent by a lower density of  the microorganism, 
and is reliable even in advanced gastric body atrophy[14,16]. 
Maastricht guidelines updates have reserved serology 
for special situations, including extensive atrophy of  the 
stomach mucosa on the basis that other tests might be 
misleading at a low bacterial density. Thus, the debate 
continues regarding the most appropriate H. pylori diag-
nostic method in atrophic gastritis. 
Lan et al[18] aimed to evaluate the site and sensitivity 
of  biopsy-based tests in terms of  degree of  gastritis with 
atrophy. Biopsy-based tests (i.e., culture, histology Giemsa 
stain and RUT) and non-invasive tests (anti-H. pylori IgG) 
were performed in 164 uninvestigated dyspepsia patients. 
The sensitivity of  biopsy-based tests decreased when the 
degree of  gastritis with atrophy increased, regardless of  
biopsy site. In moderate to severe antrum or body gastri-
tis with atrophy, additional corpus biopsy increased the 
sensitivity to 16.67%, as compared with single antrum 
biopsy. These results confirm that in moderate to severe 
gastritis with atrophy, biopsy-based test should include 
the corpus for avoiding false negative results in H. pylori 
detection.
Since the discovery of  H. pylori, pathologists have 
used different diagnostic techniques, including immu-
nohistochemical (IHC) methods and special stains, such 
as Giemsa and Warthin-Starry, on an institution- and 
laboratory-dependent basis (with variable sensitivities and 
specificities for identifying H. pylori). On the other hand, 
it is clear that IHC staining is highly sensitive and specific 
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De Martel et al[27], using data from a large Venezuelan 
cohort of  1948 adults, compared the gastric detection of  
H. pylori by polymerase chain reaction (PCR) of  the vacA 
gene in one antral biopsy, to the detection of  H. pylori by 
histopathology (HE and Giemsa staining) in five biopsies 
(antrum and corpus). Overall, H. pylori was detected in 
85% and 95% of  the subjects by PCR and histopathol-
ogy, respectively, thus confirming that histopathology on 
five biopsies is an accurate tool for H. pylori detection in 
most subjects, compared with the PCR method on one 
biopsy. However, in subjects with the most severe pre-
cancerous lesions (intestinal metaplasia type Ⅲ and dys-
plasia), PCR displayed elevated sensitivity for detecting 
the bacteria (significantly more often than histopathology 
on a single biopsy), thus suggesting its potential useful-
ness in this setting. 
Tian et al[28] reported a meta-analysis evaluating H. py-
lori diagnostic methods in patients with a partial gastrec-
tomy. The pooled sensitivity and specificity were 93 and 
85% for histology, 77 and 89% for UBT, and 79 and 94% 
for RUT, respectively, thus leading to the conclusion that 
histology was the most reliable test in this setting. Lee et 
al[4] evaluated 91 patients requiring endoscopic mucosal 
resection for early gastric cancer (GC), obtaining three 
pairs of  biopsies from the antrum, CLC and CGC. The 
sensitivity of  histology in detecting H. pylori was signifi-
cantly higher in the CGC than that in the antrum or CLC, 
suggesting that the CGC might be the optimal biopsy site 
for H. pylori in patients with extensive atrophy. 
The utility of  routine biopsy of  the gastric ulcer mar-
gin (currently performed to exclude malignancy) in diag-
nosing H. pylori infection, has recently been re-assessed 
by Lin et al[29], by examining prospectively a cohort of  50 
patients with gastric ulcer (54% uninfected). Histology, 
RUT and UBT were compared; six biopsied specimens 
from the margin of  the gastric ulcer and one specimen 
each from the antrum and body of  non-ulcerous parts 
were obtained for histology using HE staining. The di-
agnostic accuracy of  the histological examination of  the 
ulcer margin was quite good and importantly, the addi-
tion of  one specimen from the antrum or body did not 
increase its diagnostic yield, thus emphasizing its accuracy 
and usefulness for diagnosing H. pylori infection in these 
patients.
An increasing body of  evidence supports H. pylori 
colonization in the esophageal mucosa of  dyspeptic pa-
tients. Contreras et al[30] have further contributed to the 
field, with a study examining the presence of  H. pylori in 
the gastroesophageal mucosa by histology, fluorescence 
in situ hybridization (FISH) and PCR analysis of  DNA 
(using genus- and species-specific PCR primers) extracted 
from gastric and esophageal biopsies of  82 symptomatic 
Venezuelan patients. H. pylori in the stomach was de-
tected by PCR and FISH, respectively, in 61% and 90% 
of  dyspeptic patients, and in the esophagus in 70% and 
73%. By combining the results of  both methods, H. pylori 
was observed in the gastroesophageal mucosa in 86% of  
patients. These findings deserve specific attention and 
further elucidation.
Finally, the histology reporting of  gastritis of  the 
staging system OLGA (Operative Link on Gastritis As-
sessment) has also been re-examined, considering its 
relevance to the prediction of  the gastric cancer risk[31,32]. 
Carrasco et al[33] reviewed the histology of  the normal 
gastric mucosa, overviewing the role of  H. pylori in the 
multistep cascade of  GC. The role of  the OLGA staging 
system in assessing the risk of  GC was emphasized; spe-
cifically, the epigenetic bases of  chronic gastritis, mainly 
DNA methylation of  the promoter region of  E-cadherin 
in H. pylori - induced chronic gastritis and its reversion af-
ter H. pylori eradication. In addition, the authors discussed 
the finding of  circulating cell-free DNA, offering the op-
portunity for non-invasive risk assessment of  GC. 
RaPID UREaSE TEST 
The RUT is based on the production of  large amounts 
of  urease enzyme by H. pylori, which splits the urea test 
reagent to form ammonia, enabling its detection by a 
rapid indirect test. Many commercial RUTs are available, 
including gel-based tests, paper-based tests and liquid-
based tests, providing a result in 1-24 h, depending on the 
format of  the test and the bacterial density in the biopsy 
specimen. Typically, commercial RUTs have specificities 
above 95%-100%; however, the sensitivity is slightly less, 
ranging from 85%-95%[34].
Compared with histology and culture, urease tests 
are faster, cheaper and have comparable sensitivity and 
specificity in normal clinical settings. The sensitivity can, 
however, decrease in patients with bleeding peptic ulcers 
(67%-85%), as well as in patients with partial gastrectomy 
(79%)[24,28,34,35]. Formalin contamination of  forceps used 
to collect the biopsy may also contribute to reduced sen-
sitivity[24,36].
An important conclusion of  several studies is that 
enhancing the number of  biopsy fragments and/or col-
lecting them from various regions of  the stomach (antrum 
and body, from example), achieves a higher sensibility of  
the RUT[37]. Moreover, it was shown recently that com-
bining tissues prior to RUT increased the detection of  
H. pylori, compared with testing separate specimens, and 
produced faster results[38].
CULTURE
Since the discovery of  H. pylori, bacterial culture has been 
used as routine diagnostic test, being considered the gold 
standard. Currently, the Maastricht-4 Consensus Report 
recommends H. pylori culture for performing antibiotic 
susceptibility testing if  primary resistance to clarithro-
mycin is higher than 20% or after failure of  second-line 
treatment[17].
Despite its long use, culture tests remain a challenge 
because of  the fastidious nature of  the bacterium, with 
particular growth requirements of  medium and atmo-
sphere. The most commonly used media include Bru-
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cella, Columbia Wilkins-Chalgren, brain-heart infusion or 
trypticase agar bases, supplemented with sheep or horse 
blood[39]. An alternative to blood is supplementation of  
the agar base with b-cyclodextrin or yolk emulsion[40,41].
The most recent advances on H. pylori culture concern 
growth medium composition, besides the usual serum or 
blood additives. A recent study showed that supplemen-
tation of  media with cholesterol instead of  serum was 
a viable option for H. pylori growth[42]. Another original 
approach used liquid culture medium for the rapid cul-
tivation and subsequent antibiotics susceptibility testing 
of  H. pylori directly from biopsy specimens, with a final 
detection step by an enzyme linked immunosorbent assay 
(ELISA)[43].
Concerning the growth atmosphere, H. pylori is a cap-
nophilic organism that requires an atmosphere enriched 
with CO2 (varying from 5%-10%). In addition, it has 
been considered a microaerophile, but there is no general 
consensus about its specific O2 requirements[44]. A recent 
advance on this topic was made by Park et al[45], who 
showed that unlike previous reports, H. pylori may be a 
capnophilic aerobe whose growth is promoted by atmo-
spheric oxygen levels in the presence of  10% CO2.
Typically, culture of  H. pylori is performed on gastric 
biopsy samples, and because bacteria display an irregular 
distribution in the gastric mucosa, culture of  more than 
one biopsy, from the antrum and corpus, is sometimes 
mandatory, especially after antibiotic treatment. Another 
important issue to bear in mind are factors that may af-
fect the outcome of  H. pylori culture from endoscopic 
gastric mucosal specimens. Besides the issue concern-
ing bleeding peptic ulcers, for which culture has a lower 
sensitivity than in nonbleeding cases, other host-related 
factors, such as high activity of  gastritis, low bacterial 
load, drinking alcohol and the use of  histamine H2 recep-
tor blockers, have been recently described as the cause of  
failed H. pylori culture from gastric mucosa in the infected 
subjects[24,46].
Culturing from stools has been shown to be extreme-
ly difficult because of  the complex nature of  the sample 
regarding microbiota composition and shedding of  unvi-
able H. pylori cells, and this technique has been successful 
in the setting of  rapid gastrointestinal tract transit[47]. In 
a recent study, the authors were able to culture H. pylori 
in nine and 12 rectal and ileal fluids, respectively, after 
polyethylene glycol (colyte) ingestion in 20 healthy adults 
with positive UBT[48]. Other studies have looked for the 
role of  the oral cavity as a reservoir of  H. pylori. A recent 
work evaluated the occurrence of  the organism in subgin-
gival plaque and was able, by culture, to recover H. pylori 
in nine of  30 studied patients that were H. pylori positive 
with RUT and histopathological examination. Thus, they 
concluded that detection of  H. pylori in dental plaque of  
dyspeptic patients cannot be neglected and might repre-
sent a risk factor for recolonization of  the stomach after 
systemic eradication therapy[49]. The same conclusion was 
reached by another study in which H. pylori was detected 
in subgingival dental plaque of  children and their families, 
possibly acting as a “reservoir” contributing to the intra-
familial spread[50]. 
MOLECULaR METHODS
Diagnostics tests rely more and more on molecular tests, 
which can provide faster, more accurate and sensitive 
detection of  the bacterium than conventional methods, 
with the possibility of  extension to other purposes, such 
as detection of  antibiotic resistance and virulence de-
terminants, and bacterial quantification. Moreover, bio-
logical samples other than gastric biopsies can be used, 
obtained using less invasive methods, such as stool or 
oral cavity samples. Whatever the case, amplification of  
the nucleic acids by PCR is almost always present, either 
conventional PCR or, increasingly, by real-time PCR. 
H. pylori, like a few other bacteria, acquires resistance 
by mutation, which has enabled the development of  
numerous assays, in several formats, to detect mutations 
leading to resistance, especially to macrolides and fluoro-
quinolones. To detect H. pylori and resistances to fluoro-
quinolones and clarithromycin, there is a multiplex PCR 
followed by a hybridization and alkaline phosphatase 
reaction on a membrane strip (the Genotype® HelicoDR 
kit), that uses as a starting material biopsy specimens, as 
well as culture material extracted from it. The test shows 
a high sensitivity and permits detecting infection with 
multiple strains. The performance in detecting fluoroqui-
nolone-resistance strains was, however, lower than cul-
ture, emphasizing the need to expand the range of  gyrA 
mutations included in the kit[51,52]. Several real-time PCR 
based assays, using either TaqMan or FRET (Fluorescence 
Resonance Energy Transfer) are available, as in-house 
assays or commercial kits, for clarithromycin resistance, 
performed on cultured strains, directly on biopsies[53-55] or 
in stool samples. The latter is particularly useful as a non-
invasive test in pediatric populations, where a high preva-
lence of  clarithromycin-resistant strains is suspected, 
as well as for tracking the emergence of  clarithromycin 
resistance following eradication treatment[57-58]. 
Recently, a dual-priming oligonucleotide (DPO)-based 
multiplex PCR was developed to detect both H. pylori 
infection and the most common point mutations confer-
ring resistance to clarithomycin, directly on gastric biopsy 
specimens. This assay proved to be fast and does not 
require expensive instrumentation, making it valuable in 
countries with a high prevalence of  clarithromycin resis-
tance[59,60].
The detection of  clarithromycin-resistance from for-
malin-fixed, paraffin-embedded gastric biopsies has also 
been described, and is useful mostly before treatment 
when culture and susceptibility testing is not available, or 
to detect primary resistance to clarithromycin in the case 
of  failure of  an empirical therapy based on this antibiotic. 
Real-time PCR assays, as well as a peptide nucleic acid-
fluorescence in situ hybridization (PNA-FISH) method, 
have been described recently[61-63]. 
Another area of  particular interest is the detection 
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of  virulence determinants, such as the cagA (cytotoxin-
associated gene A) and the vacA (vacuolating cytotoxin) 
major toxins. Several studies showed that the risk of  
progression of  gastric preneoplastic lesions is higher in 
patients infected with strains harboring the most virulent 
cagA and vacA genotypes than in patients infected with 
the least virulent strains. Therefore, H. pylori genotyping 
may be useful to identify patients at high risk of  progres-
sion of  gastric preneoplastic lesions and who need more 
intensive surveillance[64]. Concerning vacA, a novel meth-
od for genotyping the vacA intermediate gene region 
was reported recently, using a novel primer combination 
allowing the amplification of  smaller DNA fragments 
than the original PCR, which can therefore be applied to 
paraffin-embedded biopsies. Patients infected with vacA 
i1 strains showed an increased risk of  gastric atrophy and 
gastric carcinoma, with odds ratios of  8.0 (95%CI: 2.3-27) 
and of  22 (95%CI: 7.9-63)[65].
CagA undergoes phosphorylation on tyrosines within 
the Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs at the poly-
morphic C-terminus[66]. Several studies suggest a role for 
the polymorphic CagA EPIYA-containing region in the 
pathogenicity of  H. pylori, although conflicting results 
have been reported[67,68]. The in vivo role of  this region 
was emphasized recently in a study showing that infection 
with strains harboring two or more CagA EPIYA C mo-
tifs was associated with the presence of  surface epithelial 
damage, and with atrophic gastritis and gastric carcinoma. 
Moreover, the presence of  two or more CagA EPIYA C 
motifs increased the risk of  atrophic gastritis from 7.3 
(95%CI: 2.1-25) to 12 (95%CI: 2.5-58) and of  gastric car-
cinoma from 17 (95%CI: 5.4-55) to 51 (95%CI: 13-198), 
when compared with one EPIYA C motif. Therefore, ge-
notyping H. pylori virulence determinants could represent 
a useful approach in defining severe gastric-disease risk. 
Bacterial quantification can also be important for 
clinical management of  the infection; for example, for 
monitoring the treatment outcome or in particular set-
tings, such as upper gastrointestinal bleeding[69]. 
A recently developed real-time quantitative PCR assay 
based on H. pylori ureC (single copy gene) copy number 
proved to be around 10 times more sensitive than the 
conventional PCR method. Moreover, the copy number 
of  ureC was significantly increased when overall gastritis, 
bacterial density, chronic inflammation and intestinal 
metaplasia were present[70]. Nevertheless, further studies 
are necessary to determine the optimum cut-off  point, 
making it possible to differentiate between asymptom-
atic colonization and infection with clinical implications 
for patients. These highly sensitive real-time quantitative 
PCRs can have a large application on the study of  envi-
ronmental reservoirs as well[71,72].
By improving our knowledge of  bacteria, at the mo-
lecular level, new strategies for treatment/prevention of  
bacterial-associated diseases, as well as diagnostic tests, 
can be developed. Proteomic approaches aimed at identi-
fying gene products differentially expressed in association 
with a given pathology can provide an important input 
towards understanding the pathways that are associated 
with the respective disease, contributing to the identifica-
tion of  novel therapeutic or diagnostic targets. 
Our current knowledge on the proteome of  this or-
ganism is largely based on data obtained for the soluble 
proteome[73], membrane proteome[74,75] and secreted pro-
teome[76] of  strain 26695, the first isolate to be sequenced. 
More recently, relevant contributions have made been 
through this approach, such as novel biomarkers for gas-
tric cancer and for peptic ulcer disease[77,78].
NONINVaSIVE TESTS 
Although the reliability of  both the 13C-UBT and a 
monoclonal ELISA stool test (HpSA) to diagnose H. py-
lori infection in very young children has been confirmed, 
additional background information is warranted for epi-
demiological studies in infants and toddlers.
UREa BREaTH TESTS
The 13 C-urea breath test (13C-UBT) is one of  the most 
reliable tests for diagnosing H. pylori infection. It is a 
non-invasive, simple and safe test that provides excellent 
accuracy both for the initial diagnosis of  H. pylori infec-
tion and for the confirmation of  its eradication after 
treatment. The simplicity, good tolerance and economy 
of  the citric acid test meal probably make its systematic 
use advisable. The UBT protocol may be performed with 
relatively low doses (< 100 mg) of  urea: 75 mg or even 
50 mg seem to be sufficient. With the most widely used 
protocol (with citric acid and 75 mg of  urea), excellent 
accuracy is obtained when breath samples are collected 
as early as 10-15 min after urea ingestion. A unique and 
generally proposed cut-off  level is not possible, because 
it has to be adapted to different factors, such as the 
test meal, the dose and type of  urea, or the pre-/post-
treatment setting. As positive and negative UBT results 
tend to cluster outside of  the range between 2 and 5, a 
change in cut-off  value within this range would be ex-
pected to have little effect on the clinical accuracy of  the 
test[79,80]. UBT is now marketed for use with a nondisper-
sive, isotope-selective infrared spectroscope (NDIRS) or 
laser-assisted ratio analysis (LARA), which are reliable 
and valid alternatives to isotope ratio mass spectrometry 
(IRMS) of  potential interest for epidemiologic studies 
of  children, for screening symptomatic children before 
endoscopy or assessment of  treatment efficacy. These 
devices are far smaller and cheaper, and they allow for 
in-office, near-immediate reading of  results. Validation 
studies to establish the cut-off  value for this test were 
preliminarily performed in Japan[81]; however, further data 
are needed[82,83]. 
The 13C-UBT in adults has a high sensitivity 
(88%-95%) and specificity (95%-100%)[17]. However, the 
test has shown heterogeneous accuracy in the pediatric 
population, especially in young children, with values of  
sensitivity and specificity ranging from 75% to 100%, be-
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fore and after treatment (using several protocols), despite 
being a simple and safe non-invasive test in children older 
than 6 years old[84]. Although several modifications have 
been proposed since the original description by Graham 
of  the 13C-UBT to diagnose H. pylori infection[85], in chil-
dren, performance criteria are not yet sufficiently estab-
lished[86]. In the specific age group of  younger children, 
accurate non-invasive tests for diagnosing H. pylori infec-
tion are required, as they may avoid invasive and painful 
procedures, such as endoscopy and blood sampling, and 
to overcoming the false negative results observed with 
gold standard tests (histology, culture, and RUT), where 
colonization of  the stomach may be weak and patchy. 
Potential explanations for UBT performance vari-
ability in children might include: (1) urease activity from 
the oral bacterial flora[87]; (2) differences in delta time 
(decrease in specificity if  samples obtained at 15 min in-
stead of  30 min); and (3) variability in cut-off  values. The 
administration of  13C-urea in capsules to avoid activity of  
oral bacteria, though effective in adults, is not feasible in 
infants or toddlers[88]. Finally, the cut-off  value (usually 
determined by a ROC curve) represents a crucial factor 
for the accuracy of  the test, where low cut-off  values 
might increase sensitivity but reduce specificity, and vice 
versa[81]. Additionally, the individual’s CO2 production is 
influenced by anthropometric characteristics, as well as by 
age and sex (lower in young children with relatively low 
weight and height)[89].
Leal et al[90] performed an informative systematic 
review and meta-analysis (31 articles and 135 studies 
from January 1998 to May 2009), aiming to evaluate the 
performance of  the 13C-UBT diagnostic test for H. pylori 
infection in children. Studies with at least 30 children 
and reporting the comparison of  13C-UBT against a gold 
standard for H. pylori diagnosis (H. pylori culture, histo-
logic examination, or RUT) were included for analysis. 
Children were stratified in subgroups of  < 6 and ≥ 6 
years of  age. The 13C-UBT performance meta-analyses 
showed: (1) good accuracy in all ages combined [sensitiv-
ity 95.9%, specificity 95.7%, diagnostic odds ratio (DOR) 
424.9]; (2) high accuracy in children > 6 years (sensitivity 
96.6%, specificity 97.7%, DOR 1042.7); and (3) greater 
variability in accuracy estimates and a lower specificity 
in children ≤ 6 years (sensitivity 95%, specificity 93.5%, 
DOR 224.8). The authors identified as potentially impor-
tant sources of  heterogeneity: (1) tracer dose; (2) pretest 
meal; and (3) cut-off  value, observing that a unique 
tracer dose of  50 mg of  13C-urea showed greater accu-
racy when it was adjusted to body weight (50-75 mg were 
used between studies). Accordingly, Mégraud[91] previ-
ously reported that reducing the dose from 75 to 45 mg 
in younger children resulted in improved specificity. Al-
though citric acid has demonstrated good performance in 
adults, it is not well accepted by children, and apple, or-
ange, or grape juice seem to be good alternatives. Finally, 
a cut-off  value of  6.0‰ improved overall performance in 
children younger than 6 years, as compared to a cut-off  
of  4.0 ‰ for children older than 6 years.
Pacheco et al[92] evaluated the diagnostic accuracy of  
detecting H. pylori infection of  low dose 13C-UBT with 
early sampling at pediatric age (129 patients between 
the ages of  2.1 and 19 years old, median = 11.6 years) 
submitted to upper gastrointestinal endoscopy. The 13C-
UBT was performed after a 4-hour fasting period with 
four points of  collection: baseline (T0, at 10, 20 and 30 
min) after ingestion of  25 mg 13C-urea diluted in 100 
mL of  apple juice; analysis of  exhaled breath samples 
was performed with an isotope-selective infrared spec-
trometer. The sensitivity and specificity were similar at 
T10, T20 and T30 (94.7%/96.8%; 96.2%/96.1% and 
96.2%/94.7%, respectively).
Recently, Queiroz et al[93] investigated the agreement 
between the 13C-UBT and a monoclonal ELISA (HpSA) 
to detect H. pylori antigen in stool in a prospective study 
enrolling 414 South-American infants (123 from Brazil 
and 291 from Peru) aged 6-30 mo. Breath and stool sam-
ples were obtained at intervals of  at least three-months. 
13C-UBT and stool test results concurred with each other 
in 94.86% cases (kappa coefficient = 0.90, 95%CI: 87-92). 
In the H. pylori-positive group, DOB and OD values were 
positively correlated (r = 0.62, P < 0.001, suggesting that 
both 13C-UBT and stool monoclonal test are reliable to 
diagnose H. pylori infection in very young children. 
In contrast to pediatric studies, where attention has 
been focused on methodological issues, in adult studies, 
the validity and usefulness of  UBT have increasingly been 
evaluated in a wide spectrum of  specific clinic settings. 
Olafsson et al[94] evaluated 620 UBT in 595 subjects at a 
gastroenterology clinic. UBT was negative in 526 patients, 
but: (1) 45% patients were tested < 4 wk before the end 
of  treatment; and (2) 23% of  negative results occurred 
in patients recently treated. The authors emphasized the 
need for strict protocol adherence in clinical practice for a 
fully reliable UBT assessment. Velayos et al[95] investigated 
the accuracy of  UBT performed immediately after emer-
gency endoscopy in 74 patients with peptic ulcer bleeding 
by comparing the results with those of  UBT performed 
after hospital discharge in a subset of  53 patients (gold 
standard). Although UBT carried out immediately after 
emergency endoscopy in peptic ulcer bleeding is an ef-
fective, safe and easy-to-perform procedure, the relatively 
low sensitivity and specificity suggested the requirement 
of  a subsequent control, in accordance with recommen-
dations concerning peptic ulcer bleeding[96].
Few studies using UBT have been performed in pa-
tients subjected to a partial gastrectomy, a specific group 
in which the identification of  H. pylori infection is mostly 
relevant. Wardi et al[97] evaluated the sensitivity and speci-
ficity of  the continuous UBT (BreathID) in 76 post gas-
trectomized patients (older than 18 years) (lowering the 
gastric pH by the addition of  citric acid), against RUT 
and histology as gold standards. H. pylori was positive in 
14/76 (18.4%) patients when histology was considered as 
the gold standard method. The positive predictive values 
of  the continuous UBT and the RUT were 0.64 and 0.35, 
respectively. The negative predictive value was high by 
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both the methods, 0.92 and 0.95, respectively, supporting 
the view that BreathID might have some reliability to ex-
clude H. pylori after partial gastrectomy.
STOOL aNTIGEN TESTS 
The stool antigen test is a non-invasive method to detect 
H. pylori, usually recommended when the UBT is not 
available[98]. Besides being non-invasive, the advantages 
of  using this method include the unneeded requirement 
of  expensive equipment and medical personnel, and the 
collection of  the sample at home without a visit to the 
hospital. This method is especially relevant for children’s 
access to a safe diagnosis and also for its low cost[99,100].
A meta-analysis revealed that the global sensitivity and 
specificity of  stool antigen tests are 94% (95%CI: 93-95) 
and 97% (95%CI: 96-98), respectively[101]. A prospective 
study to evaluate the efficacy of  a new EZ-STEP H. py-
lori polyclonal enzyme immunoassay (EIA) stool antigen 
test enrolled 555 patients undergoing routine checkups. 
At the optimal cut-off  value (optical density 0.160), this 
test presented high level of  sensitivity (93.1%), specificity 
(94.6%) and accuracy (93.8%)[99].
There are two types of  stool antigen tests used for 
H. pylori detection, the EIA and an assay based on immu-
nochromatography. Two new stool tests were developed 
recently[102]. These tests are the Testmate pylori antigen 
EIA, in which plastic 96-well EIA microtiter plates are 
coated with monoclonal antibody (Mab) 21G2[103], and 
the Testmate rapid pylori antigen, which is based in im-
munochromatography and is presented as a test strip. For 
the EIA test, a drop of  the suspended stool sample or a 
sample of  the diluted bacterial antigen sample is mixed 
with the peroxidase-conjugated MAb 21G2. After proper 
incubation and washing, the optical density is measured 
and considered positive if  greater than 0.100. For the test 
strip, a drop of  stool sample is applied in the specimen 
application of  the test strip. When H. pylori antigens are 
present, they form immune complexes with the red latex-
labeled MAb 21Ge and migrate by capillarity action until 
captured by the solid phase anti-mouse rabbit polyclonal 
antibodies and form a visible red test line. A control line 
is also present. After application of  these tests to 111 
stool samples, both new tests provide 100% specific-
ity, sensibility and accuracy[102], which is very promising. 
However, not all studies report these high values for sen-
sitivity and specificity. For example, the report of  Chehter 
et al[100] analyzed the stools of  75 patients and determined 
a lower sensitivity (87.2%) and specificity (44%); Irani-
khah et al[104] analyzed the stools of  103 children and ob-
tained similar values for sensitivity (85%), but improved 
specificity (83%).
Recently, five different stool antigen tests were com-
pared: the Premier Platinum HpSA Plus test  (based on 
monoclonal EIA; Meridian Bioscience, Inc, Cincinnati, 
OH, United States); the Hp Ag test (based on monoclo-
nal EIA; Dia.Pro Diagnostic Bioprobes Srl, Milano, Italy); 
the ImmunoCard STAT! HpSA test (based on monoclo-
nal lateral flow chromatography (LFC); Meridian Biosci-
ence, Europe Srl Milano, Italy); the H. pylori fecal antigen 
test (based on monoclonal LFC; Vegal Farmaceutica, Ma-
drid, Spain) and the one-step H. pylori antigen (based on 
LFC with polyclonal antibodies; IHP-602, ACON Labo-
ratories, Inc, San Diego, United States). Data comparison 
showed an uneven performance, favoring the Premier 
Platinum HpSA Plus test (sensitivity 92.2%; specificity 
94.4%). The selection of  the stool antigen assay is very 
important to achieve accurate results. 
Stool antigen tests are also useful to detect H. pylori in 
infected animal models, such as C57BL/6 mice[105].
aNTIBODY - BaSED TESTS 
Serology was one of  the first methods used for diagnosis 
of  H. pylori infection[106]. Currently, serology is recom-
mended for initial screening, requiring further confirma-
tion by histology and/or culture before treatment[107]. 
Detection of  antibodies is useful for detecting past or 
present exposure. In fact, a limitation of  serology tests 
is the failure to distinguish between past and current H. 
pylori infection[99]. Moreover, the antibody levels to H. 
pylori are significantly heritable. Thus, individual genetic 
differences of  the human host contribute substantially to 
antibody levels to H. pylori[108].
Serological tests have several advantages, namely they 
are non-invasive and they do not produce false negative 
results in patients receiving treatment (proton pump in-
hibitors and antibiotics) or presenting acute bleeding[109]. 
Blood samples are used for serology testing, detect-
ing anti-H. pylori antibodies (IgG) by ELISA. Recently, 
the performance of  29 different serological tests kits was 
compared, revealing sensitivities ranging from 55.6% to 
100%, specificities ranging from 59.6% to 97.9 %, posi-
tive predictive values ranging from 69.8% and 100%, 
and negative predictive values ranging from 68.3% and 
100%[106]. According to the goal, such as screening, initial 
diagnosis and confirmation of  another test, the most ap-
propriate kit should be chosen. Antibody-based tests for 
the detection of  H. pylori are easily available, but present 
high negative predictive value[110]. The heterogeneity of  H. 
pylori strains has been well documented, with considerable 
variation in the prevalence of  specific strains, especially 
from different geographical areas[111-113]; thus, the success 
of  a serology test depends on the use of  antigens that 
are present in H. pylori strains from a given population. 
Moreover, kits developed using H. pylori strains from 
the west are not suitable for detecting H. pylori infection 
in the East[114]. The use of  high-molecular-weight cell-
associated antigens that are conserved in H. pylori strains 
overcomes this limitation[115]. Several H. pylori immuno-
genic proteins have been presented as candidates to de-
tect infection, such as the FlidD protein[116]; multiple re-
combinant (CagA, VacA, GroEL, gGT, HcpC and UreA) 
proteins[116]; CagA[115] or Omp18[117]. 
Modifications to serology tests have been suggested, 
such as the automated immunoaffinity assay for H. pylori 
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IgG detection using purified antigen of  H. pylori immobi-
lized on magnetic nanobeads, which is faster than ELISA 
and requires a smaller volume of  serum[118]. The lateral 
flow immunoassay, an immunochromatographic assay, 
maintains the serological approach with the advantage of  
being fast, economic and requiring no additional equip-
ment or experience[119]. 
Detection of  gastrin and the serum PG Ⅰ/Ⅱ ratio 
combined with H. pylori serology is useful to predict 
gastric preneoplastic conditions[110]. The PG Ⅰ/Ⅱ ratio 
decreases with advancing extensive atrophic gastritis, 
since PG I is produced by chief  and mucous neck cells in 
the fundus glands, which are impaired in case of  gastritis 
of  the fundus; while PG Ⅱ is produced by the former 
cells and also by cardiac, pyloric and duodenal Brunner’s 
glands[120]. 
DETECTION OF H. PYLORI IN OTHER 
SPECIMENS 
Other specimens have been evaluated to determine their 
usefulness to detect H. pylori infection. These include sa-
liva[121,122], subgingival biofilm[123], dental plaque[124], gastric 
juice, gastroesophageal biopsies[125] and adenotonsillar 
tissue[126]. Contradictory results have been reported re-
garding H. pylori detection in adenotonsillar tissue, either 
favoring[127] or against[126] adenotonsillar tissue as an extra-
gastric reservoir of  H. pylori. The ability to detect H. pylori 
antibodies in saliva is lower than in blood-based serology. 
However, the use of  molecular techniques for the detec-
tion of  H. pylori infection in saliva or dental plaque may 
make these specimens attractive because they are easier to 
collect[114]. The molecular techniques include PCR[122,123] 
and PCR-denaturing gradient gel electrophoresis (PCR-
DGGE)[128]. Other techniques used to analyze these spec-
imens are the RUT, immunohistochemistry and PNA-
FISH[126]. 
The enterotest or string test was designed decades 
ago specially for children. The string test consists of  a 
gelatin capsule attached to a 90-140 cm long nylon string 
that unwinds during ingestion. Upon reaching the stom-
ach, the gelatin capsule dissolves and the string absorbs 
gastric secretions. The extraction of  the string occurs 
30-180 min later and should avoid contact with teeth and 
tongue to prevent contamination. The string may be used 
for culture (sensitivity 65% and specificity 99%) or PCR 
(sensitivity 79% and specificity 99%) for H. pylori detec-
tion[129]. 
CONCLUSION
Recent developments in both biopsy- and non-biopsy-
based diagnostic methods for H. pylori infection will 
further contribute to improving current clinical approach 
and management of  H. pylori-associated diseases. 
We predict that in the future, standard and newer 
methods will evolve to improve the diagnostic yield of  H. 
pylori infection detection in specific age groups (children 
versus adults) and clinical conditions, such as peptic ulcer 
bleeding, atrophic gastritis, post-gastrectomy status, as 
well as for wider application in epidemiological studies. 
The specific contribution of  each method to the evolving 
strategies and algorithms for evaluation and management 
of  H. pylori infection (test and treat) will remain of  para-
mount relevance.
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